Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
January 14, 2013 9:09 AM 1 min read

Accelrys Buys All Vialis AG Stock for ~$5M in Cash

by Paul Quintaro Benzinga Editor
Follow
ACCL Logo
ACCLAcco Group Holdings Ltd
$1.45-0.62%
Overview
Accelrys, Inc. (NASDAQ:
ACCL
Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
NewsM&A
), a leading provider of scientific innovation lifecycle management software, is solidifying its market leadership in the laboratory informatics space with the acquisition of its long-time partner Vialis AG, a leading systems integrator based in Liestal, Switzerland serving the pharmaceutical, biotechnology, chemicals, and agro-science industries. Vialis' deep experience implementing and supporting paperless laboratory solutions further strengthens Accelrys' position in the laboratory informatics software market and expands the company's capabilities in the downstream analytical development, quality control, and quality assurance and manufacturing areas. Under terms of the deal, Accelrys has purchased all of Vialis' outstanding stock for approximately $5 million in cash. The acquisition includes potential for additional incentive consideration of up to approximately $5 million in cash, contingent upon meeting specified growth objectives over the next three years. "With demonstrated success in improving laboratory operations by integrating core software systems critical to improving innovation – including electronic laboratory notebooks, laboratory execution systems, and laboratory information management systems – Vialis brings key domain and delivery expertise to Accelrys, and we welcome them to our team," said Accelrys President and CEO Max Carnecchia. "This acquisition is a natural complement to our two most recent software acquisitions of Velquest and Aegis Corp., furthering our strategy to deliver software solutions that optimize the laboratory-to-commercialization value chain." In addition to its systems integration services, Vialis' business process consultancy delivers process improvements in lab data management. Employing a proprietary approach to analyzing existing lab processes, Vialis' business process consultancy services help customers optimize efficiency, enhance quality by design efforts, increase compliance, maximize knowledge re- use and reduce cycle times.
ACCL Logo
ACCLAcco Group Holdings Ltd
$1.45-0.62%
Overview
Comments
Loading...